Free Trial

MarketBeat Week in Review – 11/2 - 11/6

A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.

Key Points

  • Market volatility persisted after the midterm elections as uncertainty over potential data center regulation unsettled the AI trade.
  • A strong jobs report raised expectations for a December Federal Reserve rate increase, which MarketBeat analysts say favors dividend-paying stocks with yields above inflation.
  • MarketBeat contributors covered earnings and corporate developments across companies including AbbVie, Apple, Amazon, Palantir, Meta Platforms, and Energy Transfer this week.
  • Five stocks we like better than AbbVie.

It's a rally. It's a sell-off. At the end of the week, the only thing that was clear was confusion. Investors were hoping to get clarity with the U.S. midterm elections behind them. Instead, they got more volatility.

The reason is uncertainty about future regulation surrounding data centers. The conventional wisdom suggests it may not be as bad as the worst-case scenario. But any regulation is likely to slow down a trade that looked like a runaway train.

That's likely to mean the flight to safety will continue. A strong jobs report on Friday raised the odds for the Federal Reserve to raise interest rates in December. Dividend payers may still appeal to investors seeking income, particularly those that offer a yield above the current rate of inflation.

Speaking of inflation, next week investors will get the latest reading on inflation at the consumer and producer levels. A hot number from either report will likely cement expectations for higher rates and will likely keep volatility front and center.

Articles by Thomas Hughes

AbbVie NYSE: ABBV hit a fresh high after an earnings beat and a dividend increase. But Thomas Hughes said the Humira era is fading, and he explained why its new growth engines face another test.

Oracle NYSE: ORCL may be nearing the peak of its AI spending cycle. Hughes explained what that could mean for a stock recovery.

Tempus AI NASDAQ: TEM surged on a beat-and-raise quarter, but analysts reacted with caution. Hughes explained what needs to happen for the rally to last.

Articles by Sam Quirke

Apple NASDAQ: AAPL beat estimates, but the stock sold off amid concerns about memory and AI spending. Sam Quirke pointed out the catch for investors heading into the holiday quarter.

Qualcomm NASDAQ: QCOM beat earnings, but soft guidance sent shares lower. Quirke explained why its fastest-growing businesses come with a catch.

Amazon NASDAQ: AMZN has already erased its post-earnings sell-off despite concerns over the impact of capital expenditures (CapEx) on free cash flow. Quirke asked whether the biggest opportunity is still ahead.

Articles by Chris Markoch

Marriott NASDAQ: MAR topped earnings estimates as fee growth outpaced room revenue. Chris Markoch explained why the stock is more than a bet on travel demand.

Two oil majors just reported, and the message was straightforward. Blue-chip stocks still work. Markoch pointed out why their results remind investors to keep it simple.

Palantir NASDAQ: PLTR delivered a $2.3 billion quarter, but the stock dipped after earnings. Markoch analyzed how the results put its premium valuation to the test.

Articles by Ryan Hasson

Starbucks NASDAQ: SBUX says its turnaround is done, and the numbers back it up. But Ryan Hasson explained the one catch investors shouldn’t overlook.

Big Tech is spending billions on AI, and someone is cashing those checks. Hasson highlighted five stocks that are getting paid.

Search growth is slowing at Alphabet NASDAQ: GOOGL, raising questions about how it will monetize AI. Hasson asked whether those fears are warranted.

Articles by Leo Miller

Marvell Technology NASDAQ: MRVL fell 13% on a report that it may acquire Lumentum NASDAQ: LITE. Leo Miller explained why markets are weighing the price tag of an optical swing for the fences.

CEOs at three underperforming companies just made notable trades in their own stock. Miller explained what those insider moves could signal.

Meta Platforms NASDAQ: META is planning a $100 billion push to fund its AI buildout. Miller showed why that plan has a catch for existing shareholders.

Articles by Nathan Reiff

Investors looking to play the weight-loss drug boom have more than one ETF option. Nathan Reiff compared a GLP-1-focused fund with one offering broader peptide exposure.

Waste services aren’t usually thought of as growth plays. Reiff highlighted three stocks with more growth than you might expect.

JFrog NASDAQ: FROG is pulling ahead of its software rivals in the AI race. Reiff explained why it could be the infrastructure company to beat.

Articles by Dan Schmidt

One waste giant has the momentum, while the other offers a safer dividend. Dan Schmidt explained which advantage matters more for investors.

Uranium prices are near historic highs, but Cameco NYSE: CCJ missed earnings. Schmidt explained why the stock hasn’t followed the commodity higher.

Investors are rotating away from AI after the election. Schmidt highlighted three dividend ETFs that offer different ways to navigate the sell-off.

Articles by Jeffrey Neal Johnson

Energy Transfer TXSE: ET missed earnings estimates. But Jeffrey Neal Johnson pointed out why the miss may be hiding its strongest advantage.

TeraWulf NASDAQ: WULF just landed a $19 billion deal backed by Google. Johnson provided a breakdown of why that credit backstop may be its biggest advantage.

Freeport-McMoRan NYSE: FCX is betting $4.5 billion on a major copper expansion. Johnson explained what the project means for its long-term growth.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
AbbVie (ABBV)
4.0984 of 5 stars
$292.480.4%2.37%50.42Moderate Buy$297.46
Tempus AI (TEM)
1.8186 of 5 stars
$84.7011.4%N/AN/AHold$79.37
Apple (AAPL)
3.7384 of 5 stars
$350.362.3%0.31%39.01Moderate Buy$343.74
Qualcomm (QCOM)
4.8641 of 5 stars
$174.435.5%2.11%13.76Hold$197.55
Amazon.com (AMZN)
4.8777 of 5 stars
$268.613.6%0.07%21.69Moderate Buy$321.74
Marriott International (MAR)
3.0383 of 5 stars
$418.620.5%0.70%41.78Moderate Buy$399.04
Palantir Technologies (PLTR)
4.4824 of 5 stars
$169.295.6%N/A118.62Moderate Buy$214.53
Starbucks (SBUX)
3.6768 of 5 stars
$109.373.8%2.30%49.50Hold$108.83
Alphabet (GOOGL)
4.8755 of 5 stars
$291.252.3%0.30%15.20Buy$412.51
Marvell Technology (MRVL)
4.6487 of 5 stars
$154.929.7%0.15%51.23Moderate Buy$300.09
Lumentum (LITE)
4.153 of 5 stars
$602.7211.9%N/AN/AModerate Buy$1,081.61
Meta Platforms (META)
4.9734 of 5 stars
$641.865.2%0.33%21.87Moderate Buy$833.12
JFrog (FROG)
2.6697 of 5 stars
$105.534.5%N/AN/AModerate Buy$112.43
Cameco (CCJ)
4.4044 of 5 stars
$74.594.6%0.23%112.96Moderate Buy$147.38
Energy Transfer (ET)
4.987 of 5 stars
$19.060.7%7.19%12.97Moderate Buy$24.80
TeraWulf (WULF)
3.7671 of 5 stars
$12.298.1%N/AN/AModerate Buy$29.78
Freeport-McMoRan (FCX)
4.9173 of 5 stars
$62.505.2%0.48%26.27Moderate Buy$75.30

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines